Linked Life Data

12391194

Source:http://linkedlifedata.com/resource/pubmed/id/12391194

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2002-10-22
pubmed:abstractText
Parathyroid hormone-related protein (PTH-rP), a protein produced by prostate carcinoma and other epithelial cancers, is a key agent in the development of bone metastases. We investigated whether the protein follows the self-tolerance paradigm or can be used as a target Ag for anticancer immunotherapy by investigating the immunogenicity of two HLA-A(*)02.01-binding PTH-rP-derived peptides (PTR-2 and -4) with different affinity qualities. PTH-rP peptide-specific CTL lines were generated from the PBMC of two HLA-A(*)02.01(+) healthy individuals, stimulated in vitro with PTH-rP peptide-loaded autologous dendritic cells and IL-2. The peptide-specific CTLs were able to kill PTH-rP(+)HLA-A(*)02.01(+) breast and prostate carcinoma cell lines. The two peptides were also able to elicit a strong antitumor PTH-rP-specific CTL response in HLA-A(*)02.01 (HHD) transgenic mice. The vaccinated mice did not show any sign of side effects due to cell-mediated autoimmunity or toxicity. In this study we describe two immunogenic and toxic-free PTH-rP peptides as valid candidates for the design of peptide-based vaccination strategies against prostate cancer and bone metastases from the most common epithelial malignancies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
169
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4840-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:12391194-Animals, pubmed-meshheading:12391194-Autoimmunity, pubmed-meshheading:12391194-Binding, Competitive, pubmed-meshheading:12391194-Cancer Vaccines, pubmed-meshheading:12391194-Cells, Cultured, pubmed-meshheading:12391194-Cytotoxicity, Immunologic, pubmed-meshheading:12391194-Cytotoxicity Tests, Immunologic, pubmed-meshheading:12391194-Epitopes, T-Lymphocyte, pubmed-meshheading:12391194-Female, pubmed-meshheading:12391194-HLA-A Antigens, pubmed-meshheading:12391194-HLA-A2 Antigen, pubmed-meshheading:12391194-Humans, pubmed-meshheading:12391194-Lymphocyte Activation, pubmed-meshheading:12391194-Male, pubmed-meshheading:12391194-Mice, pubmed-meshheading:12391194-Mice, Transgenic, pubmed-meshheading:12391194-Neoplasms, Experimental, pubmed-meshheading:12391194-Oligopeptides, pubmed-meshheading:12391194-Parathyroid Hormone-Related Protein, pubmed-meshheading:12391194-Peptide Hormones, pubmed-meshheading:12391194-Protein Binding, pubmed-meshheading:12391194-T-Lymphocytes, Cytotoxic, pubmed-meshheading:12391194-Tumor Cells, Cultured, pubmed-meshheading:12391194-Vaccines, Synthetic
pubmed:year
2002
pubmed:articleTitle
High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects.
pubmed:affiliation
Division of Medical Oncology, Institut National de la Santé et de la Recherche Médicale Unité d'Immunité Cellulaire Antivirale, Institut Pasteur, Paris, France. francini@unisi.it
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't